K
0.501
0.01 (2.24%)
| Previous Close | 0.490 |
| Open | 0.510 |
| Volume | 766,638 |
| Avg. Volume (3M) | 1,495,409 |
| Market Cap | 36,340,896 |
| Price / Book | 3.66 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.270 |
| Total Debt/Equity (MRQ) | 276.80% |
| Current Ratio (MRQ) | 0.290 |
| Operating Cash Flow (TTM) | -4.48 M |
| Levered Free Cash Flow (TTM) | -1.95 M |
| Return on Assets (TTM) | -151.41% |
| Return on Equity (TTM) | -1,544.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Klotho Neurosciences, Inc. | - | - |
AIStockmoo Score
-1.0
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.00 |
|
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 50.23% |
| % Held by Institutions | 2.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Arkadios Wealth Advisors | 30 Sep 2025 | 25,000 |
| Sg Americas Securities, Llc | 30 Sep 2025 | 11,949 |
| Gabelli & Co Investment Advisers, Inc. | 30 Sep 2025 | 10,000 |
| Ep Wealth Advisors, Llc | 30 Jun 2025 | 10,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2025 | Announcement | Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award |
| 16 Oct 2025 | Announcement | Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston |
| 07 Oct 2025 | Announcement | Klotho Neurosciences Announces Expiration of Letter of Intent |
| 30 Sep 2025 | Announcement | Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership |
| 08 Sep 2025 | Announcement | Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |